

ANALYSIS DONE


**2 eyes of the same person are NOT independent observations. Therefore, either do NOT mention that you took both eyes of the same subject as independent data points OR include more subjects.

- 1) Is there any BASELINE difference between the subjects in the 3 drug groups?
 - a. Age
 - b. Gender
 - c. VA
 - d. ACD
 - e. HVF
 - f. OCT
 - g. Baseline CCT
 - h. Baseline IOP (NCT)
 - i. Baseline IOP (AT)
- 2) Is there any reduction in IOP with 3 drugs over time?
 - a. IOP NCT
 - b. IOP AT 0900
 - c. IOP AT 1200
 - d. IOP AT 1500
 - e. IOP AT 1800
 - f. IOP AT 2200
 - g. IOP AT 0700
- 3) Do these 3 drugs increase CCT over time?
- 4) Do these 3 drugs reduce Peak IOP over time?
- 5) Do these drugs reduce RANGE of IOP variation over time?
- 6) Which drug is more effective (Measured as % reduction from baseline measurement)
 - a. CCT
 - b. IOP NCT
 - c. IOP AT 0900
 - d. IOP AT 1200
 - e. IOP AT 1500
 - f. IOP AT 1800
 - g. IOP AT 2200
 - h. IOP AT 0700
- 7) Is there a difference in frequency of Adverse effects between different drug groups?
 - a. Itching
 - b. Irritation
 - c. Burning sensation
 - d. DOV
 - e. Hyperaemia
 - f. Allergic conjunctivitis
 - g. Blepharitis

BASELINE PARAMETERS


AGE DISTRIBUTION

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
Age (Years)	count	30.0	30.0	30.0	0.731	Kruskal Wallis Test
	mean	52.0	50.27	52.8		
	std	7.99	7.52	10.65		
	min	41.0	40.0	40.0		
	25%	45.25	45.0	44.25		
	50%	50.0	47.0	49.0		
	75%	59.25	57.25	59.75		
	max	66.0	64.0	76.0		




GENDER

		Gender			P VALUE	TEST APPLIED
		Female	Male	All		
Drug	Latanoprost	12	18	30	0.835	Chi Square Test
	Ripasudil	14	16	30		
	Timolol	14	16	30		
	All	40	50	90		




VISUAL ACUITY

Crosstab								
			Drug			Total	P VALUE	TEST APPLIED
			Timolol	Latanoprost	Ripasudil			
Visual Acuity	6/6	Count	9	6	7	22	0.885	Fisher's Exact Test
		% of Total	10.0%	6.7%	7.8%	24.4%		
	6/9	Count	6	5	6	17		
		% of Total	6.7%	5.6%	6.7%	18.9%		
	6/12	Count	5	5	4	14		
		% of Total	5.6%	5.6%	4.4%	15.6%		
	6/18	Count	1	1	1	3		
		% of Total	1.1%	1.1%	1.1%	3.3%		
	6/24	Count	3	4	7	14		
		% of Total	3.3%	4.4%	7.8%	15.6%		
	6/36	Count	2	2	2	6		
		% of Total	2.2%	2.2%	2.2%	6.7%		
	6/60	Count	1	4	0	5		
		% of Total	1.1%	4.4%	0.0%	5.6%		
	Finger Counting at 5m	Count	2	0	2	4		
		% of Total	2.2%	0.0%	2.2%	4.4%		
	Finger Counting at 4m	Count	0	1	0	1		
		% of Total	0.0%	1.1%	0.0%	1.1%		
	Finger Counting at 3m	Count	0	1	1	2		
		% of Total	0.0%	1.1%	1.1%	2.2%		
	Finger Counting at 2m	Count	1	1	0	2		
		% of Total	1.1%	1.1%	0.0%	2.2%		
Total		Count	30	30	30	90		
		% of Total	33.3%	33.3%	33.3%	100.0%		




ACD

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
Anterior Chamber Depth	count	30.0	30.0	30.0	0.804	Kruskal Wallis Test
	mean	3.77	3.72	3.73		
	std	0.27	0.26	0.25		
	min	3.4	3.2	3.4		
	25%	3.5	3.5	3.5		
	50%	3.75	3.8	3.7		
	75%	3.98	3.8	3.8		
	max	4.3	4.2	4.5		




HVF

		HVF				P VALUE	TEST APPLIED
		Borderline	Outside Normal Limits	Within Normal Limits	All		
Drug	Latanoprost	4	5	21	30	0.506	Chi Square Test
	Ripasudil	9	6	15	30		
	Timolol	7	4	19	30		
	All	20	15	55	90		




OCT

		OCT				P VALUE	TEST APPLIED
		Borderline	Outside Normal Limits	Within Normal Limits	All		
Drug	Latanoprost	6	8	16	30	0.122	Chi Square Test
	Ripasudil	14	8	8	30		
	Timolol	8	6	16	30		
	All	28	22	40	90		




BASELINE CCT

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
CCT1	count	30.0	30.0	30.0	0.215	Kruskal Wallis Test
	mean	535.37	531.53	537.97		
	std	23.97	16.92	20.87		
	min	490.0	496.0	492.0		
	25%	520.75	519.0	528.5		
	50%	544.0	528.5	546.0		
	75%	553.0	547.0	552.75		
	max	563.0	562.0	563.0		




BASELINE IOP (NCT)

		Drug			P VALUE	TEST APPLIED
		Latanopros t	Ripasudil	Timolol		
IOP1 (NCT)	count	30.0	30.0	30.0	0.016	Kruskal Wallis Test
	mean	27.77	26.23	27.86		
	std	2.08	2.66	2.51		
	min	24.0	22.0	25.0		
	25%	26.0	25.0	26.0		
	50%	27.65	26.0	27.2		
	75%	29.0	28.0	29.0		
	max	32.0	32.0	34.8		




BASELINE IOP (AT)

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
IOP1 (9AM)	count	30.0	30.0	30.0	0.003	Kruskal Wallis Test
	mean	24.8	22.6	24.77		
	std	2.27	2.98	2.4		
	min	22.0	18.0	22.0		
	25%	24.0	20.0	24.0		
	50%	24.0	22.0	24.0		
	75%	27.5	24.0	26.0		
	max	28.0	28.0	30.0		





IOP (NCT) TIME SERIES


			IOP1 (NCT)	IOP2 (NCT)	IOP3 (NCT)	P VALUE	TEST
Drug	Timolol	Mean	27.9	23.6	21.9	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2.5	4.0	4.1		
		Median	27.2	22.5	21.0		
		Percentile 25	26.0	21.5	20.2		
		Percentile 75	29.0	24.8	22.0		
		Range	9.8	19.0	19.7		
	Latanoprost	Mean	27.8	23.8	22.5	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2.1	5.8	5.8		
		Median	27.7	22.1	21.0		
		Percentile 25	26.0	19.5	18.0		
		Percentile 75	29.0	26.0	25.4		
		Range	8.0	19.0	19.8		
	Ripasudil	Mean	26.2	24.1	22.2	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2.7	3.2	4.1		
		Median	26.0	23.5	22.0		
		Percentile 25	25.0	22.0	18.0		
		Percentile 75	28.0	26.0	24.0		
		Range	10.0	14.0	15.5		




VISIT WISE IOP (NCT) BY DRUGS








CHANGE IN IOP (NCT) of Timolol




Post Hoc Analysis for IOP (NCT) – Timolol group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.8	0.258	3.098	0.002	0.006
T1	T3	1.8	0.258	6.971	<0.001	<0.001
T2	T3	1	0.258	3.873	<0.001	<0.001

CHANGE IN IOP (NCT) of Latanoprost



Post Hoc Analysis for IOP (NCT) – Latanoprost group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.55	0.258	2.13	0.033	0.099
T1	T3	1.25	0.258	4.841	<0.001	<0.001
T2	T3	0.7	0.258	2.711	0.007	0.02


CHANGE IN IOP (NCT) of Ripasudil




Post Hoc Analysis for IOP (NCT) – Ripasudil group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.833	0.258	3.227	0.001	0.004
T1	T3	1.517	0.258	5.874	<0.001	<0.001
T2	T3	0.683	0.258	2.647	0.008	0.024


IOP 0900 hrs TIME SERIES


			IOP1 (AT, 0900 hrs)	IOP2 (AT, 0900 hrs)	IOP3 (AT, 0900 hrs)	P VALUE	TEST
Drug	Timolol	Mean	25	18	15.1	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2	5	5.8		
		Median	24	16	14.0		
		Percentile 25	24	14	12.0		
		Percentile 75	26	22	14.0		
		Range	8	22	22.0		
	Latanopros t	Mean	25	19	18.1	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2	7	7.1		
		Median	24	16	14.0		
		Percentile 25	24	14	12.0		
		Percentile 75	28	24	22.0		
		Range	6	22	24.0		
	Ripasudil	Mean	23	19	18.4	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	3	5	4.8		
		Median	22	20	18.0		
		Percentile 25	20	16	16.0		
		Percentile 75	24	22	22.0		
		Range	10	18	18.0		



VISIT WISE IOP (0900) BY DRUGS







CHANGE IN IOP (0900) OF TIMOLOL

Post Hoc Analysis for IOP (AT 0900) – Timolol group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.983	0.258	3.808	<0.001	<0.001
T1	T3	1.617	0.258	6.261	<0.001	<0.001
T2	T3	0.633	0.258	2.453	0.014	0.043

CHANGE IN IOP (0900) OF LATANOPROST


Post Hoc Analysis for IOP (AT 0900) – Latanoprost group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.5	0.258	1.936	0.053	0.158
T1	T3	1.050	0.258	4.067	<0.001	<0.001
T2	T3	0.55	0.258	2.13	0.033	0.099

CHANGE IN IOP (0900) OF RIPASUDIL


Post Hoc Analysis for IOP (AT 0900) – Ripasudil group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.767	0.258	2.969	0.003	0.009
T1	T3	1.233	0.258	4.777	<0.001	<0.001
T2	T3	0.467	0.258	1.807	0.071	0.212


IOP-1200 hrs TIME SERIES


			IOP1 (AT, 1200 hrs)	IOP2 (AT, 1200 hrs)	IOP3 (AT, 1200 hrs)	P VALUE	TEST
Drug	Timolol	Mean	24	18	14	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2	6	5		
		Median	24	16	12		
		Percentile 25	22	14	12		
		Percentile 75	26	22	14		
		Range	8	22	22		
	Latanoprost	Mean	24	19	18	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2	7	7		
		Median	24	16	14		
		Percentile 25	22	14	12		
		Percentile 75	26	22	22		
		Range	6	24	22		
	Ripasudil	Mean	22	19	18	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	3	4	5		
		Median	22	18	18		
		Percentile 25	20	16	16		
		Percentile 75	24	20	20		
		Range	12	18	18		



VISIT WISE IOP (1200) BY DRUGS







CHANGE IN IOP (1200) OF TIMOLOL

Post Hoc Analysis for IOP (AT 1200) – Timolol group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.867	0.258	3.357	0.001	0.002
T1	T3	1.733	0.258	6.713	<0.001	<0.001
T2	T3	0.867	0.258	3.357	0.001	0.002

CHANGE IN IOP (1200) OF LATANOPROST


Post Hoc Analysis for IOP (AT 1200) – Latanoprost group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.617	0.258	2.388	0.017	0.051
T1	T3	1.083	0.258	4.196	<0.001	<0.001
T2	T3	0.467	0.258	1.807	0.071	0.212

CHANGE IN IOP (1200) OF RIPASUDIL


Post Hoc Analysis for IOP (AT 1200) – Ripasudil group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.917	0.258	3.55	<0.001	0.001
T1	T3	1.183	0.258	4.583	<0.001	<0.001
T2	T3	0.267	0.258	1.033	0.302	0.905


IOP-1500 hrs TIME SERIES


			IOP1 (AT, 1500 hrs)	IOP2 (AT, 1500 hrs)	IOP3 (AT, 1500 hrs)	P VALUE	TEST
Drug	Timolol	Mean	24	18	14	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	3	5	5		
		Median	24	15	12		
		Percentile 25	22	14	12		
		Percentile 75	26	20	14		
		Range	8	22	20		
	Latanoprost	Mean	25	19	17	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2	7	7		
		Median	24	16	14		
		Percentile 25	24	14	12		
		Percentile 75	26	22	22		
		Range	6	22	22		
	Ripasudil	Mean	21	19	18	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	4	4	4		
		Median	22	18	18		
		Percentile 25	20	16	14		
		Percentile 75	24	22	20		
		Range	14	16	16		



VISIT WISE IOP (1500) BY DRUGS







CHANGE IN IOP (1500) OF TIMOLOL

Post Hoc Analysis for IOP (AT 1500) – Timolol group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.917	0.258	3.55	<0.001	0.001
T1	T3	1.683	0.258	6.52	<0.001	<0.001
T2	T3	0.767	0.258	2.969	0.003	0.009

CHANGE IN IOP (1500) OF LATANOPROST


Post Hoc Analysis for IOP (AT 1500) – Latanoprost group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.633	0.258	2.453	0.014	0..043
T1	T3	1.117	0.258	4.325	<0.001	<0.001
T2	T3	0.483	0.258	1.872	0.061	0.184

CHANGE IN IOP (1500) OF RIPASUDIL


Post Hoc Analysis for IOP (AT 1500) – Ripasudil group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.8	0.258	3.098	0.002	0.006
T1	T3	1	0.258	3.873	<0.001	<0.001
T2	T3	0.2	0.258	0.775	0.439	1


IOP – 1800 hrs TIME SERIES


			IOP1 (AT, 1800 hrs)	IOP2 (AT, 1800 hrs)	IOP3 (AT, 1800 hrs)	P VALUE	TEST
Drug	Timolol	Mean	24	18	15	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2	5	5		
		Median	24	16	14		
		Percentile 25	22	14	12		
		Percentile 75	26	22	14		
		Range	8	22	22		
	Latanoprost	Mean	24	18	17	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2	7	7		
		Median	24	14	14		
		Percentile 25	22	14	12		
		Percentile 75	26	22	24		
		Range	6	24	22		
	Ripasudil	Mean	22	19	18	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	4	4	4		
		Median	22	18	17		
		Percentile 25	20	16	14		
		Percentile 75	24	22	20		
		Range	14	16	18		



VISIT WISE IOP (1800) BY DRUGS







CHANGE IN IOP (1800) OF TIMOLOL

Post Hoc Analysis for IOP (AT 1800) – Timolol group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.967	0.258	3.744	<0.001	<0.001
T1	T3	1.583	0.258	6.132	<0.001	<0.001
T2	T3	0.617	0.258	2.388	0.017	0.051

CHANGE IN IOP (1800) OF LATANOPROST


Post Hoc Analysis for IOP (AT 1800) – Latanoprost group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.617	0.258	2.388	0.017	0.051
T1	T3	0.983	0.258	3.808	<0.001	<0.001
T2	T3	0.367	0.258	1.42	0.156	0.467

CHANGE IN IOP (1800) OF RIPASUDIL


Post Hoc Analysis for IOP (AT 1800) – Ripasudil group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.667	0.258	2.582	0.01	0.029
T1	T3	0.983	0.258	3.808	<0.001	<0.001
T2	T3	0.317	0.258	1.226	0.22	0.66


IOP- 2200hrs TIME SERIES


			IOP1 (AT, 2200 hrs)	IOP2 (AT, 2200 hrs)	IOP3 (AT, 2200 hrs)	P VALUE	TEST
Drug	Timolol	Mean	24	17	15	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	3	5	5		
		Median	24	14	14		
		Percentile 25	22	14	12		
		Percentile 75	26	22	14		
		Range	10	20	20		
	Latanoprost	Mean	24	18	18	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2	7	7		
		Median	24	16	14		
		Percentile 25	22	12	12		
		Percentile 75	26	24	22		
		Range	6	22	20		
	Ripasudil	Mean	21	19	18	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	3	4	5		
		Median	22	18	16		
		Percentile 25	20	16	16		
		Percentile 75	24	22	22		
		Range	10	16	20		



VISIT WISE IOP (2200) BY DRUGS







CHANGE IN IOP (2200) OF TIMOLOL

Post Hoc Analysis for IOP (AT 2200) – Timolol group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	1	0.258	3.873	<0.001	<0.001
T1	T3	1.55	0.258	6.003	<0.001	<0.001
T2	T3	0.55	0.258	2.13	0.033	0.099

CHANGE IN IOP (2200) OF LATANOPROST


Post Hoc Analysis for IOP (AT 2200) – Latanoprost group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.7	0.258	2.711	0.007	0.02
T1	T3	1	0.258	3.873	<0.001	<0.001
T2	T3	0.3	0.258	1.162	0.245	0.736

CHANGE IN IOP (2200) OF RIPASUDIL


Post Hoc Analysis for IOP (AT 2200) – Ripasudil group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.85	0.258	3.292	0.001	0.003
T1	T3	1	0.258	3.873	<0.001	<0.001
T2	T3	0.15	0.258	0.581	0.561	1


IOP – 0700 hrs TIME SERIES


			IOP1 (AT, 0700 hrs)	IOP2 (AT, 0700 hrs)	IOP3 (AT, 0700 hrs)	P VALUE	TEST
Drug	Timolol	Mean	24	17	14	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2	6	5		
		Median	24	16	12		
		Percentile 25	22	14	12		
		Percentile 75	26	22	14		
		Range	8	22	22		
	Latanoprost	Mean	25	18	18	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	2	7	7		
		Median	24	14	14		
		Percentile 25	24	12	12		
		Percentile 75	28	22	22		
		Range	6	20	20		
	Ripasudil	Mean	21	19	18	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	3	5	4		
		Median	22	18	17		
		Percentile 25	20	16	14		
		Percentile 75	24	20	22		
		Range	12	18	16		



VISIT WISE IOP (0700) BY DRUGS







CHANGE IN IOP (0700) OF TIMOLOL

Post Hoc Analysis for IOP (AT 0700) – Timolol group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	1.017	0.258	3.938	<0.001	<0.001
T1	T3	1.583	0.258	2.195	<0.001	<0.001
T2	T3	0.567	0.258	2.195	0.028	0.085

CHANGE IN IOP (0700) OF LATANOPROST


Post Hoc Analysis for IOP (AT 0700) – Latanoprost group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.767	0.258	2.969	0.003	0.009
T1	T3	1.083	0.258	4.196	<0.001	<0.001
T2	T3	0.317	0.258	1.226	0.22	0.66

CHANGE IN IOP (0700) OF RIPASUDIL


Post Hoc Analysis for IOP (AT 0700) – Ripasudil group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.867	0.258	3.357	0.001	0.003
T1	T3	1.183	0.258	4.583	<0.001	<0.001
T2	T3	0.317	0.258	1.226	0.22	0.66


CCT TIME SERIES


			Central Corneal Thickness 1	Central Corneal Thickness 2	Central Corneal Thickness 3	P VALUE	TEST
Drug	Timolol	Mean	538	539	539	0.230	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	21	21	22		
		Median	546	546	546		
		Percentile 25	528	523	523		
		Percentile 75	553	555	554		
		Range	71	76	74		
	Latanoprost	Mean	535	537	538	<0.001	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	24	23	23		
		Median	544	543	547		
		Percentile 25	520	519	519		
		Percentile 75	553	554	557		
		Range	73	75	73		
	Ripasudil	Mean	532	533	533	0.047	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	17	15	16		
		Median	529	530	531		
		Percentile 25	519	521	522		
		Percentile 75	548	546	548		
		Range	66	62	62		



VISIT WISE CCT BY DRUGS







CHANGE IN CCT of Timolol

Post hoc analysis not done since Friedman's test itself is not significant.

CHANGE IN CCT of Latanoprost

Post Hoc Analysis for CCT – Latanoprost group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	-0.383	0.258	-1.485	0.138	0.413
T1	T3	-1.017	0.258	-3.938	<0.001	<0.001
T2	T3	-0.633	0.258	-2.453	0.014	0.043


CHANGE IN CCT of Ripasudil

Post Hoc Analysis for CCT – Ripasudil group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	-0.25	0.258	-0.968	0.333	0.999
T1	T3	-0.6	0.258	-2.324	0.016	0.048
T2	T3	-0.35	0.258	-1.356	0.175	0.526

DO THESE DRUGS REDUCE THE RANGE OF IOP VARIATION OVER TIME?


Timolol Group

			IOP Range T1	IOP Range T2	IOP Range T3	P value	Test
Drug	Timolol	Mean	1.70	2.13	2.24	0.096	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	.88	1.04	1.55		
		Median	2.00	2.00	2.00		
		Percentile 25	2.00	2.00	2.00		
		Percentile 75	2.00	2.00	2.00		
		Minimum	0.00	0.00	0.00		
		Maximum	4.00	4.00	8.20		
		Range	4.00	4.00	8.20		




Latanoprost Group

			IOP Range T1	IOP Range T2	IOP Range T3	P value	Test
Drug	Latanoprost	Mean	1.53	2.07	1.87	0.080	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	.86	.83	.90		
		Median	2.00	2.00	2.00		
		Percentile 25	2.00	2.00	2.00		
		Percentile 75	2.00	2.00	2.00		
		Minimum	0.00	0.00	0.00		
		Maximum	2.00	4.00	4.00		
		Range	2.00	4.00	4.00		




Ripasudil Group

			IOP Range T1	IOP Range T2	IOP Range T3	P value	Test
Drug	Ripasudil	Mean	2.40	2.13	1.93	0.591	Friedman's Two-way analysis of related samples by Rank
		Standard Deviation	1.43	1.04	1.11		
		Median	2.00	2.00	2.00		
		Percentile 25	2.00	2.00	2.00		
		Percentile 75	2.00	2.00	2.00		
		Minimum	0.00	0.00	0.00		
		Maximum	6.00	4.00	4.00		
		Range	6.00	4.00	4.00		




Error Bars: 95% CI

DO THESE DRUGS REDUCE THE PEAK IOP OVER TIME?



Timolol Group

		IOP Maximum T1	IOP Maximu m T2	IOP Maximum T3	P VALUE	TEST
Timolol	Mean	25.17	18.73	16.04	<0.001	Friedman's Two-way analysis of related samples by Rank
	Standard Deviation	2.41	5.32	5.40		
	Median	24.00	16.00	14.00		
	Percentile 25	24.00	16.00	14.00		
	Percentile 75	28.00	22.00	14.00		
	Minimum	22.00	14.00	12.00		
	Maximu m	30.00	34.00	34.00		
	Range	8.00	20.00	22.00		




Post Hoc Analysis for PEAK IOP– Latanoprost group

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.983	0.258	3.808	<0.001	<0.001
T1	T3	1.617	0.258	6.261	<0.001	<0.001
T2	T3	0.633	0.258	2.453	0.014	0.043

Latanoprost group


		IOP Maximum T1	IOP Maximum T2	IOP Maximum T3	P VALUE	TEST
Latanoprost	Mean	25.27	19.80	18.47	<0.001	Friedman's Two-way analysis of related samples by Rank
	Standard Deviation	2.00	6.99	6.88		
	Median	24.00	16.00	14.00		
	Percentile 25	24.00	14.00	14.00		
	Percentile 75	28.00	24.00	24.00		
	Minimum	22.00	12.00	12.00		
	Maximum	28.00	34.00	34.00		
	Range	6.00	22.00	22.00		



Post Hoc Analysis for PEAK IOP– Latanoprost group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.517	0.258	2.001	0.045	0.136
T1	T3	1.083	0.258	4.196	<0.001	<0.001
T2	T3	0.567	0.258	2.195	0.028	0.085

Ripasudil group

		IOP Maximum T1	IOP Maximum T2	IOP Maximum T3	P VALUE	TEST
Ripasudil	Mean	22.93	20.20	19.13	<0.001	Friedman's Two-way analysis of related samples by Rank
	Standard Deviation	2.82	4.21	4.32		
	Median	22.00	20.00	18.00		
	Percentile 25	20.00	18.00	16.00		
	Percentile 75	24.00	22.00	22.00		
	Minimum	18.00	14.00	14.00		
	Maximum	28.00	30.00	30.00		
	Range	10.00	16.00	16.00		




Post Hoc Analysis for PEAK IOP– Ripasudil group						
Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
T1	T2	0.733	0.258	2.84	0.005	0.014
T1	T3	1.167	0.258	4.518	<0.001	<0.001
T2	T3	0.433	.258	1.678	0.093	0.28

PERCENTAGE CHANGE IN CCT


BETWEEN 1ST AND 2ND VISIT

		Drug			P VALUE	TEST APPLIED
		Latanopros t	Ripasudil	Timolol		
T2-T1 CCT PERCENT	count	30.0	30.0	30.0	0.914	ANOVA
	mean	0.26	0.21	0.18		
	std	0.65	0.66	0.69		
	min	-0.9	-0.91	-1.25		
	25%	-0.32	-0.19	-0.33		
	50%	0.36	0.28	0.36		
	75%	0.59	0.51	0.72		
	max	1.99	1.92	1.42		



BETWEEN 1st AND 3rd VISIT

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
T3-T1 CCT PERCENT	count	30.0	30.0	30.0	0.043	ANOVA; Test Statistic - 3.261
	mean	0.57	0.35	0.1		
	std	0.67	0.78	0.67		
	min	-1.16	-1.6	-1.15		
	25%	0.24	-0.19	-0.38		
	50%	0.55	0.37	0.1		
	75%	1.01	0.91	0.68		
	max	1.79	1.85	1.09		





Post hoc analysis

Multiple Comparisons

:


(I) Drug			Mean Differenc e (I-J)	Std. Error	Sig.	95% Confidence Interval	
						Lower Boun d	Upper Boun d
Bonferroni	Timolol	Latanopro st	-.46700*	.1829 4	.03 3	-.903 2	-.030 8
		Ripasudil	-.24600	.1829 4	.37 5	-.682 2	.1902
	Latanopro st	Timolol	.46700*	.1829 4	.03 3	.0308	.9032
		Ripasudil	.22100	.1829 4	.45 2	-.215 2	.6572
	Ripasudil	Timolol	.24600	.1829 4	.37 5	-.190 2	.6822
		Latanopro st	-.22100	.1829 4	.45 2	-.657 2	.2152

PERCENTAGE CHANGE IN IOP (NCT)



BETWEEN 1ST AND 2ND VISIT

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
T2-T1 IOP (NCT) PERCENT	count	30.0	30.0	30.0	<0.001	Kruskal Wallis Test
	mean	-14.75	-8.2	-15.41		
	std	17.47	6.72	9.45		
	min	-30.77	-20.0	-24.0		
	25%	-26.67	-11.01	-19.05		
	50%	-22.34	-9.69	-17.82		
	75%	-4.93	-8.0	-15.24		
	max	28.21	11.15	18.33		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test	Significance	Adjusted Significance
----------	----------	----------------	----------------	-----------	--------------	-----------------------

				Statistic		(Bonferroni correction)
Latanoprost	Timolol	6.417	6.744	0.951	0.341	1
Latanoprost	Ripasudil	-30.983	6.744	-4.594	<0.001	<0.001
Timolol	Ripasudil	-24.567	6.744	-3.643	<0.001	0.001

BETWEEN 1ST AND 3RD VISIT



		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
T3-T1 IOP (NCT) PERCENT	count	30.0	30.0	30.0	0.018	Kruskal Wallis Test
	mean	-19.43	-15.31	-21.45		
	std	17.95	13.32	11.27		
	min	-37.93	-46.67	-36.78		
	25%	-32.06	-21.74	-27.39		
	50%	-26.61	-14.29	-23.74		
	75%	-4.11	-9.3	-18.31		
	max	24.54	11.54	16.67		



Post hoc analysis


Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	1.417	6.744	0.210	0.834	1
Latanoprost	Ripasudil	-17.233	6.744	-2.55	0.011	0.032
Timolol	Ripasudil	-15.817	6.744	-2.345	0.019	0.057

PERCENTAGE CHANGE IN IOP (0900)



BETWEEN 1ST AND 2ND VISIT

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
T2-T1 IOP (0900) PERCENT	count	30.0	30.0	30.0	0.009	Kruskal Wallis Test
	mean	-23.23	-14.78	-27.07		
	std	23.89	14.96	16.24		
	min	-50.0	-45.45	-46.15		
	25%	-44.5	-24.52	-40.34		
	50%	-30.3	-15.38	-28.85		
	75%	1.19	-2.27	-21.84		
	max	21.43	18.18	21.43		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-2.25	6.736	-0.334	0.738	1

Timolol	Ripasudil	-18.95	6.736	-2.813	0.005	0.015
Latanoprost	Ripasudil	-16.7	6.736	-2.479	0.013	0.04

BETWEEN 1ST AND 3RD VISIT



		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
T3-T1 IOP (0900) PERCENT	count	30.0	30.0	30.0	<0.001	Kruskal Wallis Test
	mean	-28.15	-18.96	-39.75		
	std	24.07	16.71	18.15		
	min	-54.55	-54.55	-53.85		
	25%	-45.45	-27.27	-50.0		
	50%	-41.67	-21.43	-45.45		
	75%	-5.36	-10.0	-41.67		
	max	23.08	18.18	21.43		



Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-15.017	6.722	-2.234	0.025	0.076
Timolol	Ripasudil	-30.533	6.722	-4.542	<0.001	<0.001
Latanoprost	Ripasudil	-15.517	6.722	-2.308	0.021	0.063


PERCENTAGE CHANGE IN IOP (1200)



BETWEEN 1ST AND 2ND VISIT

	Drug			P VALUE	TEST APPLIED
	Latanoprost	Ripasudil	Timolol		
	t				

T2-T1 IOP (1200) PERCENT	count	30.0	30.0	30.0	0.002	Kruskal Wallis Test
	mean	-24.18	-13.69	-27.21		
	std	24.71	15.04	16.76		
	min	-54.55	-44.44	-45.45		
	25%	-42.56	-22.22	-36.36		
	50%	-33.33	-13.4	-33.33		
	75%	-10.42	-8.52	-21.84		
	max	23.08	30.0	21.43		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-1.483	6.736	-0.22	0.826	1
Timolol	Ripasudil	-21.567	6.736	-3.202	0.001	0.003

Latanoprost	Ripasudil	-20.083	6.736	-2.982	0.003	0.009
-------------	-----------	---------	-------	--------	-------	-------

BETWEEN 1ST AND 3RD VISIT


		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
T3-T1 IOP (1200) PERCENT	count	30.0	30.0	30.0	<0.001	Kruskal Wallis Test
	mean	-29.05	-16.75	-41.31		
	std	23.64	16.66	16.04		
	min	-58.33	-40.0	-54.55		
	25%	-45.45	-31.82	-50.0		
	50%	-41.67	-18.18	-45.45		
	75%	-10.71	-9.32	-41.67		
	max	23.08	30.0	14.29		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-16.517	6.723	-2.457	0.014	0.042
Timolol	Ripasudil	-37.283	6.723	-5.546	<0.001	<0.001
Latanoprost	Ripasudil	-20.767	6.723	-3.089	0.002	0.006


PERCENTAGE CHANGE IN IOP (1500)





BETWEEN 1ST AND 2ND VISIT

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
T2-T1 IOP (1500) PERCENT	count	30.0	30.0	30.0	<0.001	Kruskal Wallis Test
	mean	-24.18	-11.93	-27.98		
	std	26.19	16.11	17.11		
	min	-50.0	-33.33	-46.15		
	25%	-45.45	-20.0	-39.62		
	50%	-33.33	-16.67	-33.56		
	75%	-10.42	0.0	-22.32		
	max	30.77	30.0	23.08		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-1.533	6.736	-0.228	0.82	1
Timolol	Ripasudil	-23.817	6.736	-3.536	<0.001	<0.001
Latanoprost	Ripasudil	-22.283	6.736	-3.308	0.001	0.003

BETWEEN 1ST AND 3RD VISIT

	Drug			P VALUE	TEST APPLIED
	Latanoprost	Ripasudil	Timolol		

T3-T1 IOP (1500) PERCENT	count	30.0	30.0	30.0	<0.001	Kruskal Wallis Test
	mean	-30.91	-14.74	-40.97		
	std	24.68	17.37	17.31		
	min	-58.33	-40.0	-57.14		
	25%	-50.0	-25.0	-49.04		
	50%	-41.67	-18.18	-45.45		
	75%	-13.39	-9.32	-41.67		
	max	23.08	30.0	23.08		





Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-11.75	6.732	-1.745	0.081	0.243
Timolol	Ripasudil	-36.4	6.732	-5.407	<0.001	<0.001

Latanoprost	Ripasudil	-24.65	6.732	-3.661	<0.001	<0.001
-------------	-----------	--------	-------	--------	--------	--------


PERCENTAGE CHANGE IN IOP (1800)





BETWEEN 1ST AND 2ND VISIT

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
T2-T1 IOP (1800) PERCENT	count	30.0	30.0	30.0	0.002	Kruskal Wallis Test
	mean	-25.75	-11.45	-28.17		
	std	25.61	17.45	17.15		
	min	-54.55	-50.0	-50.0		
	25%	-45.45	-19.55	-40.34		
	50%	-36.36	-9.16	-33.33		
	75%	-5.77	0.0	-21.43		
	max	23.08	18.18	21.43		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	0.283	6.736	0.042	0.966	1
Timolol	Ripasudil	-21.167	6.736	-3.142	0.002	0.006
Latanoprost	Ripasudil	-20.883	6.736	-3.1	0.002	0.006

BETWEEN 1ST AND 3RD VISIT

	Drug			P VALUE	TEST APPLIED
	Latanoprost	Ripasudil	Timolol		

T3-T1 IOP (1800) PERCENT	count	30.0	30.0	30.0	<0.001	Kruskal Wallis Test
	mean	-30.12	-16.1	-39.36		
	std	24.68	16.25	16.66		
	min	-54.55	-45.45	-53.85		
	25%	-45.98	-28.24	-50.0		
	50%	-45.45	-18.18	-41.67		
	75%	-5.36	-2.08	-36.36		
	max	23.08	15.38	21.43		





Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
----------	----------	-------------------	-------------------	---------------------------	--------------	--

Latanoprost	Timolol	-8.1	6.724	-1.205	0.228	0.685
Timolol	Ripasudil	-32.15	6.724	-4.782	<0.001	<0.001
Latanoprost	Ripasudil	-24.05	6.724	-3.577	<0.001	<0.001


PERCENTAGE CHANGE IN IOP (2200)





BETWEEN 1ST AND 2ND VISIT

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
T2-T1 IOP (2200) PERCENT	count	30.0	30.0	30.0	0.001	Kruskal Wallis Test
	mean	-25.32	-12.71	-30.22		
	std	25.02	15.19	17.48		
	min	-58.33	-40.0	-50.0		
	25%	-45.45	-19.55	-41.25		
	50%	-33.33	-10.0	-36.36		
	75%	-3.84	-7.69	-21.43		
	max	23.08	20.0	15.38		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-4.633	6.738	-0.688	0.492	1
Timolol	Ripasudil	-23.917	6.738	-3.55	<0.001	0.001
Latanoprost	Ripasudil	-19.283	6.738	-2.862	0.004	0.013

BETWEEN 1ST AND 3RD VISIT

	Drug			P VALUE	TEST APPLIED
	Latanoprost	Ripasudil	Timolol		

T3-T1 IOP (2200) PERCENT	count	30.0	30.0	30.0	<0.001	Kruskal Wallis Test
	mean	-28.32	-15.83	-40.19		
	std	23.85	18.03	16.3		
	min	-53.85	-44.44	-57.14		
	25%	-45.45	-29.32	-49.46		
	50%	-38.46	-18.18	-45.45		
	75%	-10.09	-8.33	-36.88		
	max	23.08	30.0	15.38		





Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-14.433	6.731	-2.144	0.032	0.096
Timolol	Ripasudil	-34.917	6.731	-5.187	<0.001	<0.001

Latanoprost	Ripasudil	-20.483	6.731	-3.043	0.002	0.006
-------------	-----------	---------	-------	--------	-------	-------


PERCENTAGE CHANGE IN IOP (0700)





BETWEEN 1ST AND 2ND VISIT

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
T2-T1 IOP (0700) PERCENT	count	30.0	30.0	30.0	<0.001	Kruskal Wallis Test
	mean	-26.67	-11.34	-28.34		
	std	23.05	17.36	19.23		
	min	-53.85	-33.33	-50.0		
	25%	-45.45	-19.55	-40.34		
	50%	-36.36	-11.8	-33.33		
	75%	-10.42	-8.52	-21.43		
	max	15.38	44.44	30.77		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-1.6	6.737	-0.237	0.812	1
Timolol	Ripasudil	-23.9	6.737	-3.548	<0.001	0.001
Latanoprost	Ripasudil	-22.3	6.737	-3.31	0.001	0.003

BETWEEN 1ST AND 3RD VISIT

		Drug			P VALUE	TEST APPLIED
		Latanoprost	Ripasudil	Timolol		
T3-T1 IOP (0700)	count	30.0	30.0	30.0	<0.001	Kruskal Wallis Test
	mean	-30.49	-15.79	-40.22		


PERCENT	std	23.38	16.57	19.08		
	min	-53.85	-40.0	-57.14		
	25%	-49.04	-27.27	-49.46		
	50%	-42.26	-20.72	-45.45		
	75%	-10.71	-8.52	-41.67		
	max	23.08	33.33	30.77		



Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-11.25	6.724	-1.673	0.094	0.283
Timolol	Ripasudil	-35.15	6.724	-5.227	<0.001	<0.001
Latanoprost	Ripasudil	-23.9	6.724	-3.554	<0.001	0.001

DIURNAL VARIATION OVER TIME




IS THERE A DIFFERENCE IN FREQUENCY OF ADRS IN DIFFERENT DRUG GROUPS?

Overall ADR frequency

ADR	FREQUENCY	PERCENT
Itching	2	2.22%
Irritation	2	2.22%
Burning Sensation	4	4.44%
Hyperaemia	30	33.33%
Allergic Conjunctivitis	2	2.22%
Diminution of vision	2	2.22%
Blepharitis	2	2.22%


Itching

VISIT			Drug			Total	P VALUE	TEST
			Timolo l	Latanopros t	Ripasudi l			
Baselin e	Itching	Absent	30	28	30	88	0.331	Fisher's Exact Test
		Presen t	0	2	0	2		
	Total		30	30	30	90		
4 Weeks	Itching	Absent	30	30	30	90	NA	NA
	Total		30	30	30	90		
12 Weeks	Itching	Absent	30	30	30	90	NA	NA
	Total		30	30	30	90		
Overall	Irritatio n	Absent	30	28	30	88	0.331	Fisher's Exact Test
		Presen t	0	2	0	2		
	Total		30	30	30	90		




Irritation

VISIT			Drug			Total	P VALUE	TEST
			Timolo l	Latanopros t	Ripasudi l			
Baselin e	Irritatio n	Absent	30	30	28	88	0.331	Fisher's Exact Test
		Presen t	0	0	2	2		
	Total		30	30	30	90		
4 Weeks	Irritatio n	Absent	30	30	30	90	NA	NA
	Total		30	30	30	90		
12 Weeks	Irritatio n	Absent	30	30	30	90	NA	NA
	Total		30	30	30	90		
Overall	Irritatio n	Absent	30	30	28	88	0.331	Fisher's Exact Test
		Presen t	0	0	2	2		
	Total		30	30	30	90		




Burning Sensation

VISIT			Drug			Total	P VALUE	TEST
			Timolo l	Latanopro st	Ripasud il			
Baselin e	Burning Sensatio n	Absent	28	30	30	88	0.326	Fisher's Exact Test
		Presen t	2	0	0	2		
	Total		30	30	30	90		
4 Weeks	Burning Sensatio n	Absent	28	30	30	88	0.326	Fisher's Exact Test
		Presen t	2	0	0	2		
	Total		30	30	30	90		
12 Weeks	Burning Sensatio n	Absent	30	30	30	90	NA	NA
	Total		30	30	30	90		
Overall	Burning Sensatio n	Absent	26	30	30	86	0.035	Fisher's Exact Test
		Presen t	4	0	0	4		
	Total		30	30	30	90		



Hyperaemia


VISIT			Drug			Total	P VALUE	TEST
			Timolol	Latanoprost	Ripasudil			
Baseline	Hyperaemia	Absent	28	28	16	72	<0.001	Fisher's Exact Test
		Present	2	2	14	18		
	Total		30	30	30	90		
4 Weeks	Hyperaemia	Absent	30	26	26	82	0.119	Fisher's Exact Test
		Present	0	4	4	8		
	Total		30	30	30	90		
12 Weeks	Hyperaemia	Absent	28	28	30	86	0.54	Fisher's Exact Test
		Present	2	2	0	4		
	Total		30	30	30	90		
Overall	Hyperaemia	Absent	26	22	12	60	0.004	Fisher's Exact Test
		Present	4	8	18	30		
	Total		30	30	30	90		



Allergic Conjunctivitis


VISIT			Drug			Total	P VALUE	TEST
			Timol ol	Latanopro st	Ripasud il			
Baselin e	Allergic Conjunctivit is	Absent	30	30	30	90	NA	NA
	Total		30	30	30	90		
4 Weeks	Allergic Conjunctivit is	Absent	30	30	28	88	0.326	Fisher's Exact Test
		Prese nt	0	0	2	2		
	Total		30	30	30	90		
12 Weeks	Allergic Conjunctivit is	Absent	30	30	30	90	NA	NA
	Total		30	30	30	90		
Overal l	Allergic Conjunctivit	Absent	30	30	28	88	0.331	Fisher's Exact Test
		Prese	0	0	2	2		

	is	nt						
	Total		30	30	30	90		



Diminution of vision


VISIT			Drug			Total	P VALUE	TEST
			Timolol	Latanoprost	Ripasudil			
Baseline	DO V	Absent	30	30	30	90	NA	NA
	Total		30	30	30	90		
4 Weeks	DO V	Absent	28	30	30	88	0.326	Fisher's Exact Test
		Present	2	0	0	2		
	Total		30	30	30	90		
12 Weeks	DO V	Absent	30	30	30	90	NA	NA
	Total		30	30	30	90		
Overall	DO V	Absent	28	30	30	88	0.331	Fisher's Exact Test
		Present	2	0	0	2		
	Total		30	30	30	90		



Blepharitis

VISIT			Drug			Total	P VALUE	TEST
			Timolo l	Latanopros t	Ripasudi l			
Baseline	Blephariti s	Absent	30	30	30	90	NA	NA
	Total		30	30	30	90		
4 Weeks	Blephariti s	Absent	30	30	30	90	NA	NA
	Total		30	30	30	90		
12 Weeks	Blephariti s	Absent	30	30	28	88	0.326	Fisher's Exact Test
		Presen t	0	0	2	2		
	Total		30	30	30	90		
Total	Blephariti s	Absent	30	30	26	86	0.326	Fisher's Exact Test
		Presen t	0	0	4	4		
	Total		30	30	30	90		


NUMBER OF SUBJECTS REPORTING BLEPHARITIS



HOW MUCH WAS THE CHANGE IN IOP IN THE 3 DRUG GROUPS AND WAS THE CHANGE DIFFERENT IN DIFFERENT DRUG GROUPS?

T2 IOP (NCT) -T1 IOP(NCT)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T2_T1_NC T	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-4.23	-3.98	-2.12		
	Standard Deviation	2.84	4.85	1.71		
	Percentil e 25	-5.20	-7.00	-3.00		
	Median	-4.95	-6.50	-3.00		
	Percentil e 75	-4.00	-.50	-2.00		
	Maximu m	5.50	7.70	2.90		
	Minimum	-7.80	-8.30	-5.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
----------	----------	-------------------	-------------------	---------------------------	--------------	--

Latanoprost	Timolol	5	6.724	.744	0.457	1
Latanoprost	Ripasudil	-31.3	6.724	-4.655	<0.001	<0.001
Timolol	Ripasudil	-26.3	6.74	-3.912	<0.001	<0.001


T3 IOP (NCT) -T2 IOP(NCT)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T3_T2_NC T	Count	30	30	30	0.33	Kruskal Wallis Test
	Mean	-1.73	-1.32	-1.92		
	Standard Deviation	1.10	1.40	2.75		
	Percentil e 25	-2.10	-2.00	-2.00		
	Median	-1.65	-1.00	-1.00		
	Percentil e 75	-.80	-.30	-.50		
	Maximu m	-.20	1.00	1.20		
	Minimum	-5.00	-4.00	-11.00		



T3 IOP (NCT) -T1 IOP(NCT)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T3_T1_NC T	Count	30	30	30	0.007	Kruskal Wallis Test
	Mean	-5.96	-5.30	-4.04		
	Standard Deviation	3.49	4.97	3.67		
	Percentil e 25	-7.50	-8.80	-5.00		
	Median	-6.90	-7.45	-4.00		
	Percentil e 75	-4.50	-.20	-2.00		
	Maximu m	5.00	6.70	3.00		
	Minimum	-12.80	-11.00	-14.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	0.317	6.739	.047	0.963	1
Latanoprost	Ripasudil	-18.533	6.739	-2.75	0.006	0.018
Timolol	Ripasudil	-18.217	6.739	-2.703	0.007	0.021

T2 IOP (0900) -T1 IOP (0900)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T2_T1_0900	Count	30	30	30	0.002	Kruskal Wallis Test
	Mean	-6.50	-5.53	-3.27		
	Standard Deviation	3.95	5.91	3.26		
	Percentil e 25	-10.00	-10.00	-6.00		
	Median	-7.50	-7.00	-4.00		
	Percentil e 75	-6.00	2.00	0.00		
	Maximu m	6.00	6.00	4.00		
Minimum		-12.00	-14.00	-10.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-3.35	6.673	-0.502	0.616	1
Timolol	Ripasudil	-22.05	6.673	-3.304	0.001	0.003
Latanoprost	Ripasudil	-18.7	6.673	-2.802	0.005	0.015

T3 IOP (0900) -T2 IOP (0900)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T3_T2_0900	Count	30	30	30	0.006	Kruskal Wallis Test
	Mean	-3.16	-1.20	-.93		
	Standard Deviation	3.19	1.63	1.36		
	Percentil e 25	-4.00	-2.00	-2.00		
	Median	-3.00	-2.00	-1.00		
	Percentil e 75	0.00	0.00	0.00		
	Maximu m	2.20	2.00	2.00		
	Minimum	-10.00	-4.00	-4.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-15.417	6.418	-2.402	0.016	0.049

Latanoprost	Ripasudil	-4.167	6.418	-0.649	0.516	1
Timolol	Ripasudil	-19.583	6.418	-3.051	0.002	0.007

T3 IOP (0900) -T1 IOP (0900)

		Drug			P VALUE	TEST
		Timolol	Latanoprost	Ripasudil		
T3_T1_0900	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-9.66	-6.73	-4.20		
	Standard Deviation	4.69	5.88	3.65		
	Percentile 25	-12.00	-12.00	-6.00		
	Median	-10.00	-10.00	-5.00		
	Percentile 75	-10.00	0.00	-2.00		
	Maximum	6.00	6.00	4.00		
	Minimum	-16.00	-12.00	-12.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-14.317	6.672	-2.146	0.032	0.096

Timolol	Ripasudil	-32.483	6.672	-4.869	<0.001	0.001
Latanoprost	Ripasudil	-18.167	6.672	-2.723	0.006	0.018

T2 IOP (1200) -T1 IOP (1200)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T2_T1_1200	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-6.40	-5.67	-3.00		
	Standard Deviation	4.05	6.06	3.23		
	Percentil e 25	-8.00	-10.00	-4.00		
	Median	-8.00	-8.00	-3.00		
	Percentil e 75	-6.00	-2.00	-2.00		
	Maximu m	6.00	6.00	6.00		
	Minimum	-10.00	-12.00	-8.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-2.167	6.671	-0.325	0.745	1

Timolol	Ripasudil	-23.583	6.671	-3.535	<0.001	0.001
Latanoprost	Ripasudil	-21.417	6.671	-3.211	0.001	0.004

T3 IOP (1200) -T2 IOP (1200)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T3_T2_1200	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-3.53	-1.20	-.67		
	Standard Deviation	2.71	1.79	1.69		
	Percentil e 25	-4.00	-2.00	-2.00		
	Median	-2.00	-2.00	0.00		
	Percentil e 75	-2.00	0.00	0.00		
	Maximu m	0.00	2.00	2.00		
	Minimum	-10.00	-4.00	-4.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni)
----------	----------	-------------------	-------------------	---------------------------	--------------	--

						correction)
Latanoprost	Timolol	-21.567	6.451	-3.343	0.001	0.003
Timolol	Ripasudil	-28.183	6.451	-4.369	<0.001	<0.001
Latanoprost	Ripasudil	-6.617	6.451	-1.026	0.305	1

T3 IOP (1200) -T1 IOP (1200)

		Drug			P VALUE	TEST
		Timolol	Latanoprost	Ripasudil		
T3_T1_1200	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-9.93	-6.87	-3.67		
	Standard Deviation	4.12	5.75	3.72		
	Percentile 25	-12.00	-10.00	-6.00		
	Median	-10.00	-10.00	-4.00		
	Percentile 75	-10.00	-2.00	-2.00		
	Maximum	4.00	6.00	6.00		
	Minimum	-14.00	-14.00	-10.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
----------	----------	----------------	----------------	---------------------	--------------	---

Latanoprost	Timolol	-17.05	6.659	-2.561	0.01	0.031
Timolol	Ripasudil	-37.6	6.659	-5.647	<0.001	<0.001
Latanoprost	Ripasudil	-20.55	6.659	-3.086	0.002	0.006

T2 IOP (1500) -T1 IOP (1500)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T2_T1_1500	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-6.60	-5.80	-2.60		
	Standard Deviation	4.17	6.48	3.37		
	Percentil e 25	-10.00	-10.00	-4.00		
	Median	-8.00	-8.00	-4.00		
	Percentil e 75	-6.00	-2.00	0.00		
	Maximu m	6.00	8.00	6.00		
	Minimum	-12.00	-14.00	-8.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-1.5	6.683	-0.224	0.822	1
Timolol	Ripasudil	-25.6	6.683	-3.83	<0.001	0.001
Latanoprost	Ripasudil	-24.1	6.683	-3.606	<0.001	<0.001

T3 IOP (1500) -T2 IOP (1500)

		Drug			P VALUE	TEST
		Timolol	Latanoprost	Ripasudil		
T3_T2_1500	Count	30	30	30	0.002	Kruskall Wallis Test
	Mean	-3.27	-1.67	-.67		
	Standard Deviation	2.95	2.35	2.06		
	Percentile 25	-6.00	-4.00	-2.00		
	Median	-2.00	-2.00	0.00		
	Percentile 75	-2.00	0.00	0.00		
	Maximum	0.00	2.00	2.00		
	Minimum	-10.00	-6.00	-6.00		




Post hoc analysis

Sample 1	Sample 2	Test	Standard	Std.	Significance	Adjusted
----------	----------	------	----------	------	--------------	----------

		Statistic	Error	Test Statistic		Significance (Bonferroni correction)
Latanoprost	Timolol	-13.017	6.525	-1.995	0.046	0.138
Timolol	Ripasudil	-22.983	6.525	-3.523	<0.001	0.001
Latanoprost	Ripasudil	-9.967	6.525	-1.528	0.127	0.380

T3 IOP (1500) -T1 IOP (1500)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T3_T1_1500	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-9.87	-7.47	-3.27		
	Standard Deviation	4.61	6.06	3.69		
	Percentil e 25	-12.00	-12.00	-6.00		
	Median	-10.00	-10.00	-4.00		
	Percentil e 75	-10.00	-2.00	-2.00		
	Maximu m	6.00	6.00	6.00		
	Minimum	-16.00	-14.00	-8.00		




Post hoc analysis

Sample 1	Sample 2	Test	Standard	Std.	Significance	Adjusted
----------	----------	------	----------	------	--------------	----------

		Statistic	Error	Test Statistic		Significance (Bonferroni correction)
Latanoprost	Timolol	-10.567	6.679	-1.582	0.114	0.341
Timolol	Ripasudil	-36.03	6.679	-5.395	<0.001	<0.001
Latanoprost	Ripasudil	-25.467	6.679	-3.813	<0.001	<0.001

T2 IOP (1800) -T1 IOP (1800)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T2_T1_180 0	Count	30	30	30	0.001	Kruskal Wallis Test
	Mean	-6.67	-6.07	-2.60		
	Standard Deviation	4.15	6.36	3.61		
	Percentil e 25	-10.00	-10.00	-4.00		
	Median	-8.00	-8.00	-2.00		
	Percentil e 75	-6.00	0.00	0.00		
	Maximu m	6.00	6.00	4.00		
	Minimum	-12.00	-14.00	-10.00		




Post hoc analysis

Sample 1	Sample 2	Test	Standard	Std.	Significance	Adjusted
----------	----------	------	----------	------	--------------	----------

		Statistic	Error	Test Statistic		Significance (Bonferroni correction)
Latanoprost	Timolol	-0.767	6.688	-0.115	0.909	1
Timolol	Ripasudil	-22.683	6.688	-3.392	0.001	0.002
Latanoprost	Ripasudil	-21.917	6.688	-3.277	0.001	0.003


T3 IOP (1800) -T2 IOP (1800)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T3_T2_180 0	Count	30	30	30	0.078	Kruskall Wallis Test
	Mean	-2.80	-1.07	-1.00		
	Standard Deviation	2.95	2.08	2.39		
	Percentil e 25	-6.00	-2.00	-2.00		
	Median	-2.00	-1.00	0.00		
	Percentil e 75	0.00	0.00	0.00		
	Maximu m	2.00	2.00	4.00		
	Minimum	-8.00	-6.00	-6.00		



T3 IOP (1800) -T1 IOP (1800)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T3_T1_180 0	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-9.47	-7.13	-3.60		
	Standard Deviation	4.39	5.96	3.73		
	Percentil e 25	-12.00	-12.00	-6.00		
	Median	-10.00	-10.00	-4.00		
	Percentil e 75	-8.00	0.00	0.00		
	Maximu m	6.00	6.00	4.00		
	Minimum	-14.00	-14.00	-10.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-10.217	6.67	-1.532	0.126	0.377
Timolol	Ripasudil	-32.833	6.67	-4.923	<0.001	<0.001
Latanoprost	Ripasudil	-22.617	6.67	-3.391	0.001	0.003

T2 IOP (2200) -T1 IOP (2200)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T2_T1_220 0	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-7.23	-5.93	-2.73		
	Standard Deviation	4.26	6.07	3.22		
	Percentil e 25	-10.00	-10.00	-4.00		
	Median	-8.00	-8.00	-2.00		
	Percentil e 75	-6.00	0.00	-2.00		
	Maximu m	4.00	6.00	4.00		
	Minimum	-12.00	-14.00	-10.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-5.883	6.695	-0.879	0.38	1
Timolol	Ripasudil	-26.417	6.695	-3.946	<0.001	<0.001
Latanoprost	Ripasudil	-20.533	6.695	-3.07	0.002	0.006

T3 IOP (2200) -T2 IOP (2200)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T3_T2_220 0	Count	30	30	30	0.027	Kruskall Wallis Test
	Mean	-2.53	-.73	-.67		
	Standard Deviation	3.06	2.07	2.12		
	Percentil e 25	-6.00	-2.00	-2.00		
	Median	-2.00	0.00	0.00		
	Percentil e 75	0.00	0.00	0.00		
	Maximu m	2.00	4.00	2.00		
	Minimum	-8.00	-6.00	-6.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-14.233	6.506	-2.188	0.029	0.086
Timolol	Ripasudil	-15.867	6.506	-2.439	0.015	0.044
Latanoprost	Ripasudil	-1.633	6.506	-0.251	0.802	1

T3 IOP (2200) -T1 IOP (2200)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T3_T1_220 0	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-9.77	-6.67	-3.40		
	Standard Deviation	4.42	5.79	3.97		
	Percentil e 25	-12.00	-10.00	-6.00		
	Median	-10.00	-10.00	-4.00		
	Percentil e 75	-8.00	-2.00	-2.00		
	Maximu m	4.00	6.00	6.00		
Minimum		-16.00	-14.00	-10.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-14.533	6.672	-2.178	0.029	0.088
Timolol	Ripasudil	-35.317	6.672	-5.293	<0.001	<0.001
Latanoprost	Ripasudil	-20.783	6.672	-3.115	0.002	0.006

T2 IOP (0700) -T1 IOP (0700)

		Drug			P VALUE	TEST
		Timolol	Latanoprost	Ripasudil		
T2_T1_0700	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-6.70	-6.40	-2.47		
	Standard Deviation	4.68	5.69	3.55		
	Percentile 25	-10.00	-10.00	-4.00		
	Median	-8.00	-8.00	-2.00		
	Percentile 75	-6.00	-2.00	-2.00		
	Maximum	8.00	4.00	8.00		
	Minimum	-12.00	-14.00	-8.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-2.067	6.693	-0.309	0.757	1
Timolol	Ripasudil	-25.833	6.693	-3.86	<0.001	<0.001
Latanoprost	Ripasudil	-23.767	6.693	-3.551	<0.001	0.001

T3 IOP (0700) -T2 IOP (0700)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T3_T2_0700	Count	30	30	30	0.016	Kruskal Wallis Test
	Mean	-2.93	-.93	-.93		
	Standard Deviation	3.18	2.15	2.08		
	Percentil e 25	-4.00	-2.00	-2.00		
	Median	-3.00	0.00	-1.00		
	Percentil e 75	0.00	0.00	0.00		
	Maximu m	2.00	2.00	2.00		
	Minimum	-10.00	-6.00	-6.00		




Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-15.817	6.532	-2.421	0.015	0.046
Timolol	Ripasudil	-16.583	6.532	-2.539	0.011	0.033
Latanoprost	Ripasudil	0.767	6.532	0.117	0.9	1

T3 IOP (0700) -T1 IOP (0700)

		Drug			P VALUE	TEST
		Timolo l	Latanopros t	Ripasudi l		
T3_T1_0700	Count	30	30	30	<0.001	Kruskal Wallis Test
	Mean	-9.63	-7.33	-3.40		
	Standard Deviation	4.92	5.74	3.45		
	Percentil e 25	-12.00	-12.00	-6.00		
	Median	-10.00	-10.00	-4.00		
	Percentil e 75	-10.00	-2.00	-2.00		
	Maximu m	8.00	6.00	6.00		
Minimum		-16.00	-14.00	-8.00		



Post hoc analysis

Sample 1	Sample 2	Test Statistic	Standard Error	Std. Test Statistic	Significance	Adjusted Significance (Bonferroni correction)
Latanoprost	Timolol	-11.617	6.669	-1.674	0.094	0.282
Timolol	Ripasudil	-35.983	6.669	-5.395	<0.001	<0.001
Latanoprost	Ripasudil	-24.817	6.669	-3.721	<0.001	0.001

